MX2011001384A - Composiciones y metodos para tratar trastornos psiquiatricos. - Google Patents
Composiciones y metodos para tratar trastornos psiquiatricos.Info
- Publication number
- MX2011001384A MX2011001384A MX2011001384A MX2011001384A MX2011001384A MX 2011001384 A MX2011001384 A MX 2011001384A MX 2011001384 A MX2011001384 A MX 2011001384A MX 2011001384 A MX2011001384 A MX 2011001384A MX 2011001384 A MX2011001384 A MX 2011001384A
- Authority
- MX
- Mexico
- Prior art keywords
- psychiatric disorders
- methods
- compositions
- disorders
- treating psychiatric
- Prior art date
Links
- 208000020016 psychiatric disease Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 239000001961 anticonvulsive agent Substances 0.000 abstract 2
- 239000003368 psychostimulant agent Substances 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2008904016A AU2008904016A0 (en) | 2008-08-06 | Treatment for individuals with low dose anti-epileptic drugs or litium-based salts | |
| AU2008904021A AU2008904021A0 (en) | 2008-08-06 | Therapeutic combinations for psychological disorders | |
| PCT/AU2009/001000 WO2010015029A1 (en) | 2008-08-06 | 2009-08-06 | Compositions and methods for treating psychiatric disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011001384A true MX2011001384A (es) | 2011-09-27 |
Family
ID=41663218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011001384A MX2011001384A (es) | 2008-08-06 | 2009-08-06 | Composiciones y metodos para tratar trastornos psiquiatricos. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20110207718A1 (https=) |
| EP (1) | EP2331088A4 (https=) |
| JP (1) | JP2011529923A (https=) |
| CN (1) | CN102170874A (https=) |
| AU (1) | AU2009279372A1 (https=) |
| CA (1) | CA2732131A1 (https=) |
| MX (1) | MX2011001384A (https=) |
| WO (1) | WO2010015029A1 (https=) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060159743A1 (en) * | 2001-10-25 | 2006-07-20 | Depomed, Inc. | Methods of treating non-nociceptive pain states with gastric retentive gabapentin |
| US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| TWI312285B (en) * | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US20090176882A1 (en) | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
| US9533938B2 (en) | 2007-01-31 | 2017-01-03 | Biosuccess Biotech Co., Ltd. | Compositions and methods of use of phorbol esters for the treatment of stroke |
| AU2007346591A1 (en) | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of ADHD |
| MX2011001384A (es) | 2008-08-06 | 2011-09-27 | Gosforth Ct Holdings Pty Ltd | Composiciones y metodos para tratar trastornos psiquiatricos. |
| ES2865504T3 (es) | 2008-10-16 | 2021-10-15 | Univ Johns Hopkins | Procedimientos y composiciones para la mejora de la función cognitiva |
| US20120095048A1 (en) * | 2009-02-20 | 2012-04-19 | Region Midt Jylland | Allosteric binding compounds |
| ES2758554T3 (es) | 2009-12-08 | 2020-05-05 | Univ Case Western Reserve | Aminoácidos gama para tratamiento de trastornos oculares |
| WO2011143721A1 (en) * | 2010-05-21 | 2011-11-24 | Gosforth Centre (Holdings) Pty Ltd | Compositions and methods for treating neurodegenerative disorders |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| EP2672822A4 (en) * | 2011-02-09 | 2014-08-27 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTIONS |
| US9682073B2 (en) | 2011-05-19 | 2017-06-20 | Gilrose Pharmaceuticals, Llc | Pre-frontal cortex processing disorder gait and limb impairments treatment |
| US20140163070A1 (en) | 2012-05-17 | 2014-06-12 | Bruce Roseman | Treatment for cerebral palsy impaired speech in children |
| US8883815B2 (en) | 2011-05-19 | 2014-11-11 | Gilrose Pharmaceuticals, Llc | Treatment for cerebral palsy impaired speech in children |
| US10085414B2 (en) | 2011-05-19 | 2018-10-02 | Gilrose Pharmaceuticals, Llc | Pre-frontal cortex processing disorder speech, gait and limb impairments treatment |
| US9040082B2 (en) | 2011-06-24 | 2015-05-26 | K-Pax Pharmaceuticals, Inc. | Compositions and methods for treatment of chronic fatigue |
| GB201111712D0 (en) * | 2011-07-08 | 2011-08-24 | Gosforth Ct Holdings Pty Ltd | Pharmaceutical compositions |
| RU2480214C1 (ru) * | 2011-09-22 | 2013-04-27 | Валентина Ивановна Ахапкина | Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов |
| NZ727304A (en) * | 2012-01-18 | 2018-08-31 | Biosuccess Biotech Co Ltd | Compositions and methods of use of phorbol esters for the treatment of stroke |
| EP2806867A4 (en) * | 2012-01-27 | 2015-09-02 | Catalyst Pharmaceutical Partners Inc | METHOD FOR TREATING TOURETTE SYNDROME WITH GABA AMINO TRANSFERASE INACTIVORS |
| EP2829270B1 (en) | 2012-03-23 | 2020-11-11 | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China | Joint product containing synephrine and topiramate |
| CN103316026B (zh) | 2012-03-23 | 2016-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 含芬特明和托吡酯的联合产品及其制备方法 |
| TW201408294A (zh) * | 2012-07-05 | 2014-03-01 | Merz Pharma Gmbh & Co Kgaa | (r)-苯基披喇瑟盪於治療帕金森氏症之用除 |
| ES2691092T3 (es) | 2012-08-21 | 2018-11-23 | Janssen Pharmaceutica Nv | Anticuerpos contra la risperidona y uso de los mismos |
| WO2014031656A1 (en) | 2012-08-21 | 2014-02-27 | Ortho-Clinical Diagnostics, Inc | Antibodies to olanzapine haptens and use thereof |
| PL2888592T3 (pl) | 2012-08-21 | 2018-03-30 | Janssen Pharmaceutica Nv | Przeciwciała względem kwetiapiny i ich zastosowania |
| JP6131414B2 (ja) | 2012-08-21 | 2017-05-24 | ヤンセン ファーマシューティカ エヌ．ベー． | アリピプラゾールのハプテン及びイムノアッセイにおけるそれらの使用 |
| CA2882562C (en) | 2012-08-21 | 2019-08-27 | Eric Hryhorenko | Antibodies to aripiprazole and use thereof |
| JP6450314B2 (ja) | 2012-08-21 | 2019-01-09 | ヤンセン ファーマシューティカ エヌ．ベー． | クエチアピンハプテンに対する抗体及びその使用 |
| CA2882596C (en) | 2012-08-21 | 2019-05-14 | Ortho-Clinical Diagnostics, Inc. | Antibodies to olanzapine and use thereof |
| EP2888284B1 (en) * | 2012-08-21 | 2022-07-06 | Janssen Pharmaceutica NV | Antibodies to risperidone haptens and use thereof |
| JP2015529199A (ja) | 2012-08-21 | 2015-10-05 | オルソ−クリニカル ダイアグノスティクス，インコーポレイティド | パリペリドンハプテンに対する抗体及びその使用 |
| JP2015527365A (ja) | 2012-08-21 | 2015-09-17 | オルソ−クリニカル ダイアグノスティクス，インコーポレイティド | パリペリドンに対する抗体及びその使用 |
| JP6389176B2 (ja) | 2012-08-21 | 2018-09-12 | ヤンセン ファーマシューティカ エヌ．ベー． | アリピプラゾールハプテンに対する抗体及びその使用 |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| JP6433482B2 (ja) | 2013-03-15 | 2018-12-05 | エージンバイオ， インコーポレイテッド | 認知機能を改善するための方法および組成物 |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| BR112015023116A2 (pt) | 2013-03-15 | 2017-07-18 | Melior Discovery Inc | composto, composição, formulação para administração oral, método de tratamento de um distúrbio, e, uso de um composto |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| EP2875810A1 (en) * | 2013-11-20 | 2015-05-27 | Biocodex | Pharmacological treatment of obsessive-compulsive disorder using Stiripentol or a similar compound |
| EP2886116A1 (en) * | 2013-12-18 | 2015-06-24 | Biocodex | Benzodioxol derivatives for use in the treatment of attention deficit and/or hyperactivity |
| CA2932301A1 (en) * | 2013-12-25 | 2015-07-02 | Fujimoto Co., Ltd. | Prophylactic and therapeutic agent for attention-deficit/hyperactivity disorder |
| WO2015153263A1 (en) * | 2014-04-02 | 2015-10-08 | Yale University | Compositions and methods to treat addiction |
| EP3160445B1 (en) | 2014-06-26 | 2021-10-20 | Island Breeze Systems Ca, LLC | Mdi related products and methods of use |
| GB201416017D0 (en) * | 2014-09-10 | 2014-10-22 | New Royal Holloway & Bedford | An Anticonvulsant Compound |
| CN107111673B (zh) * | 2014-09-29 | 2021-03-23 | 周格尼克斯国际有限公司 | 控制药物分配的控制系统 |
| CN107206093A (zh) * | 2015-01-28 | 2017-09-26 | 韩国真耐瑞斯有限公司 | 用于治疗神经精神类障碍的组合物及方法 |
| WO2016191288A1 (en) | 2015-05-22 | 2016-12-01 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| EP3319603B1 (en) * | 2015-07-08 | 2021-11-17 | Gilrose Pharmaceuticals, LLC | Use of methylphenidate for the treatment of gait and limb impairment secondary to pre-frontal cortex processing disorder |
| CN106361734A (zh) * | 2015-07-25 | 2017-02-01 | 云南帕精生物科技有限公司 | 一类治疗精神分裂症药物 |
| JP6983161B2 (ja) * | 2015-09-15 | 2021-12-17 | プラクシス・バイオリサーチ・エルエルシー | フェンカンファミンのプロドラッグ |
| CN106562945A (zh) * | 2015-10-11 | 2017-04-19 | 云南帕精生物科技有限公司 | 一类治疗帕金森病药物 |
| CA3008048C (en) * | 2015-12-11 | 2023-11-14 | Aarhus Universitet | Rufinamide for use in the treatment of myotonia |
| EP3390449A1 (en) | 2015-12-17 | 2018-10-24 | Janssen Pharmaceutica N.V. | Antibodies to risperidone and use thereof |
| US10435478B2 (en) | 2015-12-17 | 2019-10-08 | Janssen Pharmaceutica Nv | Antibodies to quetiapine and use thereof |
| WO2017112701A1 (en) | 2015-12-22 | 2017-06-29 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| ES3024232T3 (en) | 2015-12-22 | 2025-06-04 | Zogenix International Ltd | Fenfluramine compositions and methods of preparing the same |
| CN105456214A (zh) * | 2015-12-30 | 2016-04-06 | 蔡惠文 | 甲磺酸沙芬酰胺片 |
| EP3455203B1 (en) * | 2016-05-12 | 2021-09-22 | Research Triangle Institute | Vinylogous phenethylamines as neurotransmitter releasers |
| SG11201900975XA (en) | 2016-08-24 | 2019-03-28 | Zogenix International Ltd | Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same |
| JP2020519594A (ja) * | 2017-05-09 | 2020-07-02 | ゾゲニクス インターナショナル リミテッド | フェンフルラミンを用いるドゥーゼ症候群の治療方法 |
| WO2019026019A1 (en) * | 2017-08-03 | 2019-02-07 | Therapeutic Adjuncts Inc. | USE OF 3-METHYLMETHCATHINONE |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| EP4230197A3 (en) * | 2017-10-23 | 2024-01-24 | Cerebral Therapeutics LLC | High concentration medicant solutions for treating neurological disorders |
| CA3081199A1 (en) * | 2017-11-14 | 2019-05-23 | Osaka University | Cognitive impairment diagnostic apparatus and cognitive impairment diagnostic program |
| WO2019216919A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| EA202191079A1 (ru) | 2018-11-19 | 2021-09-20 | Зодженикс Интернэшнл Лимитед | Способы лечения синдрома ретта с применением фенфлурамина |
| US12377112B2 (en) | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| WO2020214960A1 (en) * | 2019-04-18 | 2020-10-22 | Prevep Llc | Therapeutic combinations, liquid pharmaceutical compositions, kits for their preparation, and methods of their use |
| US12491200B2 (en) | 2019-05-23 | 2025-12-09 | Igc Pharma Ip, Llc | Compositions and methods using cannabinoids for treating stammering/stuttering and symptoms of Tourette syndrome |
| HRP20231735T1 (hr) | 2019-08-26 | 2024-03-15 | Period Pill Bv | Liječenje simptoma izazvanih menstrualnim ciklusom |
| US12014835B2 (en) * | 2020-02-19 | 2024-06-18 | Vanderbilt University | Methods for evaluating therapeutic benefit of combination therapies |
| RU2743876C1 (ru) * | 2020-05-19 | 2021-03-01 | Татьяна Евгеньевна Ефремова | Способ реабилитации детей и подростков с поведенческими и эмоциональными нарушениями, страдающих психическими расстройствами |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| AU2021397628A1 (en) * | 2020-12-09 | 2023-07-20 | Eysz, Inc. | Systems and methods for monitoring and managing neurological diseases and conditions |
| GB202101462D0 (en) * | 2021-02-03 | 2021-03-17 | Sanchez Hector Mario | Combination therapy for treating executive function disorders |
| WO2022217066A1 (en) * | 2021-04-09 | 2022-10-13 | The Johns Hopkins University | Treatment methods and compositions comprising perampanel |
| US20220354822A1 (en) * | 2021-05-05 | 2022-11-10 | Mind Medicine, Inc. | Mdma enantiomers |
| US12518388B2 (en) | 2021-05-28 | 2026-01-06 | Blinktbi, Inc. | Systems and methods for eyelid localization |
| WO2022265534A1 (ru) * | 2021-06-18 | 2022-12-22 | Гиви Иванович ИКАЕВ | Способ коррекции психического состояния больного шизофренией |
| JP2024524605A (ja) * | 2021-07-08 | 2024-07-05 | エヌエルエス、ファーマシューティクス、アクチエンゲゼルシャフト | クライネ－レヴィン症候群の治療における使用のためのベネジン、ピペリジン，２－ベンズヒドリル－３－ヒドロキシ－ｎ－メチル－，塩酸塩およびその誘導体 |
| WO2023092044A2 (en) | 2021-11-17 | 2023-05-25 | Terran Biosciences, Inc. | Phenethylamine compounds salts, polymorphic forms and methods of use thereof |
| CA3239514A1 (en) * | 2021-12-09 | 2023-06-15 | Matthew J. Baggott | Specialized combinations for mental disorders or mental enhancement |
| US20250375129A1 (en) * | 2022-02-11 | 2025-12-11 | Blinktbi, Inc. | Use of blink reflex for attention-deficit/hyperactivity disorder (adhd) response monitoring and/or treatment selection |
| EP4611738A1 (en) * | 2022-12-05 | 2025-09-10 | Lykos Therapeutics, Inc. | Compositions comprising mdma and methods of using same |
| CN116831580B (zh) * | 2023-08-31 | 2023-12-01 | 北京中科心研科技有限公司 | 识别抑郁情绪障碍的计算设备应用、装置及可穿戴设备 |
| US20250182612A1 (en) * | 2023-11-30 | 2025-06-05 | Toyota Motor Engineering & Manufacturing North America, Inc. | Systems and methods for providing assistance to hearing-impaired pedestrians |
| US12475781B2 (en) | 2023-12-08 | 2025-11-18 | Toyota Motor Engineering & Manufacturing North America, Inc. | Systems and methods for detecting impaired decision-making pedestrians |
| WO2025196662A1 (en) | 2024-03-20 | 2025-09-25 | Clearmind Labs Corp. | Compositions and methods for treating eating disorders |
| US12605388B2 (en) | 2024-09-25 | 2026-04-21 | Azurity Pharmaceuticals Ireland Limited | Lamotrigine salts, co-crystals, and compositions |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2957880A (en) | 1953-12-23 | 1960-10-25 | Ciba Pharm Prod Inc | Process for the conversion of stereoisomers |
| IT1188212B (it) | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
| US4891223A (en) | 1987-09-03 | 1990-01-02 | Air Products And Chemicals, Inc. | Controlled release delivery coating formulation for bioactive substances |
| IT1237904B (it) | 1989-12-14 | 1993-06-18 | Ubaldo Conte | Compresse a rilascio a velocita' controllata delle sostanze attive |
| CA2041774C (en) | 1990-11-27 | 1994-04-19 | Mircea A. Mateescu | Use of cross-linked amylose as a matrix for the slow release of biologically active compounds |
| US5603956A (en) | 1990-11-27 | 1997-02-18 | Labopharm Inc. | Cross-linked enzymatically controlled drug release |
| US5326570A (en) | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
| GB9209599D0 (en) | 1992-05-02 | 1992-06-17 | Fisons Corp | Novel therapy for the treatment of parkinsons disease |
| GB9215043D0 (en) | 1992-07-15 | 1992-08-26 | Flow Inc K | Fluid mass flow meters |
| US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
| US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
| US5397574A (en) | 1993-10-04 | 1995-03-14 | Andrx Pharmaceuticals, Inc. | Controlled release potassium dosage form |
| US5399358A (en) | 1993-11-12 | 1995-03-21 | Edward Mendell Co., Inc. | Sustained release formulations for 24 hour release of metroprolol |
| US5419917A (en) | 1994-02-14 | 1995-05-30 | Andrx Pharmaceuticals, Inc. | Controlled release hydrogel formulation |
| US5458887A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
| US5458888A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
| US5399359A (en) | 1994-03-04 | 1995-03-21 | Edward Mendell Co., Inc. | Controlled release oxybutynin formulations |
| EP0788346B9 (en) | 1994-03-18 | 2007-02-14 | Supernus Pharmaceuticals, Inc. | Emulsified drug delivery systems |
| US5399362A (en) | 1994-04-25 | 1995-03-21 | Edward Mendell Co., Inc. | Once-a-day metoprolol oral dosage form |
| US5464633A (en) | 1994-05-24 | 1995-11-07 | Jagotec Ag | Pharmaceutical tablets releasing the active substance after a definite period of time |
| US6103263A (en) | 1994-11-17 | 2000-08-15 | Andrx Pharmaceuticals, Inc. | Delayed pulse release hydrogel matrix tablet |
| US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
| US5567441A (en) | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
| US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
| DE69735002T2 (de) | 1996-10-25 | 2006-10-26 | Shire Laboratories, Inc. | Osmotisches Verabreichungssystem für lösliche Dosen |
| US5837379A (en) | 1997-01-31 | 1998-11-17 | Andrx Pharmaceuticals, Inc. | Once daily pharmaceutical tablet having a unitary core |
| CA2216215A1 (en) | 1997-04-05 | 1998-10-05 | Isa Odidi | Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity |
| CA2261787C (en) | 1997-05-30 | 2006-11-14 | Laboratorios Phoenix U.S.A., Inc. | Multi-layered osmotic device |
| US5885616A (en) | 1997-08-18 | 1999-03-23 | Impax Pharmaceuticals, Inc. | Sustained release drug delivery system suitable for oral administration |
| US6096340A (en) | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| US5916595A (en) | 1997-12-12 | 1999-06-29 | Andrx Pharmaceutials, Inc. | HMG co-reductase inhibitor |
| US20020102291A1 (en) | 1997-12-15 | 2002-08-01 | Noven Pharmaceuticals, Inc. | Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
| US6099859A (en) | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
| US6106862A (en) | 1998-08-13 | 2000-08-22 | Andrx Corporation | Once daily analgesic tablet |
| US6099862A (en) | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
| US6673367B1 (en) | 1998-12-17 | 2004-01-06 | Euro-Celtique, S.A. | Controlled/modified release oral methylphenidate formulations |
| US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
| AR026610A1 (es) * | 1999-12-01 | 2003-02-19 | Ucb Sa | Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central |
| US6417184B1 (en) * | 2000-09-19 | 2002-07-09 | David M. Ockert | Triple drug therapy for the treatment and prevention of acute or chronic pain |
| US8354438B2 (en) * | 2001-08-08 | 2013-01-15 | Michael Chez | Neurological functions |
| WO2003013514A1 (en) | 2001-08-08 | 2003-02-20 | Carn-Aware Llc | Improving neurological functions |
| CA2459146A1 (en) * | 2001-08-30 | 2003-03-13 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors |
| US20040242671A1 (en) | 2001-10-08 | 2004-12-02 | Renee Grimee | Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug |
| FR2837100B1 (fr) | 2002-03-18 | 2004-07-23 | Flamel Tech Sa | Comprimes a bases de microcapsules a liberation modifiee |
| WO2004002462A2 (en) | 2002-06-27 | 2004-01-08 | Warner-Lambert Company Llc | Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder |
| WO2004078162A1 (en) * | 2003-01-31 | 2004-09-16 | Elan Pharma International Ltd. | Nanoparticulate topiramate formulations |
| FR2861990B1 (fr) | 2003-11-10 | 2006-02-10 | Nouveaux Produits Pharma | Comprimes faiblement doses a reseau de polymeres |
| DK2036546T3 (en) | 2004-08-23 | 2018-12-17 | Pejo Iserlohn Heilmittel Und Diaet Gmbh & Co Kg | Psychostimulants containing a pharmaceutical composition |
| MX2007013882A (es) * | 2005-05-06 | 2008-01-28 | Portela & Ca Sa | Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso. |
| DE102006015734A1 (de) | 2006-04-04 | 2007-10-11 | Hermann, Holger Lars, Dr. | Kombinationspräparate aus Modafinil, Ritalin und Topiramat und deren Derivaten zur Behandlung von Kokainabhängigkeit und/oder Impulskontrollstörung |
| US8679540B2 (en) | 2006-06-09 | 2014-03-25 | Flamel Technologies | Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications |
| CA2662123C (en) | 2006-08-30 | 2015-12-01 | Jagotec Ag | Controlled release oral dosage formulations comprising a core and one or more barrier layers |
| AU2007346591A1 (en) | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of ADHD |
| WO2009014762A1 (en) * | 2007-07-25 | 2009-01-29 | The Regents Of The University Of Colorado | Central administration of stable formulations of therapeutic agents for cns conditions |
| WO2009029308A1 (en) * | 2007-08-27 | 2009-03-05 | University Of Virginia Patent Foundation | Medication combinations for the treatment of alcoholism and drug addiction |
| US20110065674A1 (en) | 2008-05-14 | 2011-03-17 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| MX2011001384A (es) | 2008-08-06 | 2011-09-27 | Gosforth Ct Holdings Pty Ltd | Composiciones y metodos para tratar trastornos psiquiatricos. |
| AU2011215870B2 (en) | 2010-02-09 | 2016-01-28 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| WO2011143721A1 (en) | 2010-05-21 | 2011-11-24 | Gosforth Centre (Holdings) Pty Ltd | Compositions and methods for treating neurodegenerative disorders |
-
2009
- 2009-08-06 MX MX2011001384A patent/MX2011001384A/es not_active Application Discontinuation
- 2009-08-06 JP JP2011521411A patent/JP2011529923A/ja active Pending
- 2009-08-06 AU AU2009279372A patent/AU2009279372A1/en not_active Abandoned
- 2009-08-06 WO PCT/AU2009/001000 patent/WO2010015029A1/en not_active Ceased
- 2009-08-06 US US13/057,628 patent/US20110207718A1/en not_active Abandoned
- 2009-08-06 CN CN2009801390755A patent/CN102170874A/zh active Pending
- 2009-08-06 CA CA2732131A patent/CA2732131A1/en not_active Abandoned
- 2009-08-06 EP EP09804384A patent/EP2331088A4/en not_active Withdrawn
-
2015
- 2015-04-06 US US14/679,559 patent/US10028971B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2331088A4 (en) | 2011-10-12 |
| WO2010015029A1 (en) | 2010-02-11 |
| US10028971B2 (en) | 2018-07-24 |
| CA2732131A1 (en) | 2010-02-11 |
| US20160000815A1 (en) | 2016-01-07 |
| CN102170874A (zh) | 2011-08-31 |
| JP2011529923A (ja) | 2011-12-15 |
| AU2009279372A1 (en) | 2010-02-11 |
| EP2331088A1 (en) | 2011-06-15 |
| US20110207718A1 (en) | 2011-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011001384A (es) | Composiciones y metodos para tratar trastornos psiquiatricos. | |
| MX2008009947A (es) | Composiciones farmaceuticas que comprenden dextrometorfano y quinidina para el tratamiento de depresion, ansiedad y trastornos neurodegenerativos. | |
| GB2463833A (en) | Methods and compositions for the treatment of neurological disorders | |
| LUC00011I1 (https=) | ||
| WO2006001877A3 (en) | Combination treatment for neurodegenerative disorders comprising r-flurbiprofen | |
| WO2007025286A3 (en) | Therapy procedure for drug delivery for trigeminal pain | |
| WO2008054544A3 (en) | Method for delivery across the blood brain barrier | |
| ATE510538T1 (de) | Zusammensetzungen und verfahren für nervenschutz | |
| NZ594140A (en) | C5ar antagonists | |
| MX340807B (es) | Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. | |
| CY1115725T1 (el) | Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων | |
| TW200733976A (en) | Method for the treatment of cognitive dysfunction | |
| TW200728300A (en) | Therapeutic agents | |
| TW200635580A (en) | Methods of treatment and prevention | |
| UA97289C2 (ru) | Соединения и их композиция как модуляторы gpr119 активности |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |